Latest Period
Q1 2026
Security Snapshot
CRISPR Therapeutics AG - Common Stock (CRSP) Institutional Ownership
CUSIP: H17182108
13F Institutional Holders and Ownership History from Q1 2016 to Q1 2026
Institutions Reporting
488
Shares (Excl. Options)
77,146,160
Price
$47.57
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- CRSP on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 77,146,160
- Total 13F value
- $3,668,208,568
- Portfolio coverage rank
- 0%
- Share change
- +549,921
- Value change
- +$18,886,145
- Number of holders
- 488
- Shares outstanding
- 96,669,746
- SEC-reported price per share
- $52.75
- Insider filing price
- $52.75
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- CRSP - CRISPR Therapeutics AG - Common Stock is tracked under CUSIP H17182108.
- 488 institutions reported positions in Q1 2026.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 476 to 488 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $4,012,545,309 to $3,668,208,568.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 488 institutions filings for Q1 2026.
Security key
H17182108
Latest holder period
Q1 2026
13F holders
488
13D/G owners
5
CIK / CUSIP context first
Open Q1 2026 holders
CRSP full holder history
CRISPR Therapeutics AG SEC filings
CRISPR Therapeutics AG company facts
CRISPR Therapeutics AG insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP H17182108:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
5
Security
CRSP
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ARK Investment Management LLC | 12% | +9.4% | $538,189,046 | +$72,622,740 | 11,313,623 | +16% | ARK Investment Management LLC | 31 Mar 2026 |
| ORBIS INVESTMENT MANAGEMENT LTD | 6.3% | +1.7% | $333,925,337 | +$8,546,133 | 6,090,194 | +2.6% | ORBIS INVESTMENT MANAGEMENT LTD | 31 Mar 2026 |
| BlackRock, Inc. | 6.9% | $288,553,541 | 5,932,433 | BlackRock, Inc. | 30 Jun 2025 | |||
| Capital World Investors | 5.1% | $270,280,537 | 4,929,428 | Capital World Investors | 31 Mar 2026 | |||
| Capital International Investors | 1.2% | -89% | $62,235,477 | -$269,926,929 | 1,186,794 | -81% | Capital International Investors | 30 Jan 2026 |
As of 31 Mar 2026, 488 institutional investors reported holding 77,146,160 shares of CRISPR Therapeutics AG - Common Stock (CRSP). This represents 80% of the company’s total 96,669,746 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
66%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| ARK Investment Management LLC | 12% | 11,313,623 | +7.5% | 4.2% | $538,189,027 |
| BlackRock, Inc. | 7.9% | 7,680,073 | +2.3% | 0.01% | $365,341,072 |
| Orbis Allan Gray Ltd | 6.3% | 6,106,011 | +2.6% | 1.2% | $290,462,944 |
| Capital World Investors | 4.9% | 4,725,037 | 0.03% | $224,770,010 | |
| STATE STREET CORP | 4.1% | 3,982,500 | +6.1% | 0.01% | $189,447,525 |
| GSK plc | 3.3% | 3,220,627 | 0% | 26% | $153,205,226 |
| T. Rowe Price Investment Management, Inc. | 3.1% | 2,952,595 | -8.5% | 0.1% | $140,455,000 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.5% | 2,377,164 | +5.7% | 0.01% | $113,102,369 |
| SR One Capital Management, LP | 2.1% | 2,038,763 | 0% | 11% | $96,983,956 |
| FMR LLC | 2% | 1,954,694 | +0.04% | 0% | $92,984,816 |
| Amova Asset Management Americas, Inc. | 1.9% | 1,853,875 | -5.3% | 1.2% | $88,188,834 |
| Sumitomo Mitsui Trust Group, Inc. | 1.9% | 1,853,875 | -5.3% | 0.06% | $88,188,834 |
| UBS Group AG | 1.8% | 1,762,530 | -30% | 0.01% | $83,843,552 |
| TWO SIGMA INVESTMENTS, LP | 1.5% | 1,483,051 | +215% | 0.06% | $70,548,736 |
| EcoR1 Capital, LLC | 1.4% | 1,389,276 | 0% | 2.8% | $66,087,859 |
| Capital International Investors | 1.2% | 1,186,794 | -80% | 0.01% | $56,455,791 |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.2% | 1,142,543 | 0% | 0% | $54,350,771 |
| NEA Management Company, LLC | 1.1% | 1,058,570 | 0% | 2.9% | $50,356,175 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.1% | 1,039,349 | +0.89% | 0.01% | $49,441,832 |
| BANK OF AMERICA CORP /DE/ | 1% | 983,072 | -10% | 0% | $46,764,747 |
| LOOMIS SAYLES & CO L P | 1% | 968,135 | +7.7% | 0.06% | $46,054,182 |
| NORTHERN TRUST CORP | 0.83% | 802,181 | +6.2% | 0.01% | $38,159,750 |
| MORGAN STANLEY | 0.69% | 668,141 | +0.16% | 0% | $31,783,481 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.61% | 593,406 | -31% | 0.04% | $28,228,323 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.57% | 546,826 | 0% | 0% | $26,012,513 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
40
Latest
Q1 2026
Rows shown
1-25 of 40
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 77,146,160 | $3,668,208,568 | +$18,886,145 | $47.57 | 488 |
| 2025 Q4 | 76,493,280 | $4,012,545,309 | +$35,291,528 | $52.44 | 476 |
| 2025 Q3 | 72,232,014 | $4,681,196,062 | +$29,481,399 | $64.81 | 435 |
| 2025 Q2 | 72,314,703 | $3,517,677,257 | +$428,897,837 | $48.64 | 426 |
| 2025 Q1 | 64,129,300 | $2,183,568,653 | -$16,834,672 | $34.03 | 388 |
| 2024 Q4 | 64,443,699 | $2,536,549,693 | +$179,624,639 | $39.36 | 398 |
| 2024 Q3 | 59,826,628 | $2,811,325,020 | +$6,501,203 | $46.98 | 407 |
| 2024 Q2 | 59,510,276 | $3,214,159,736 | +$50,043,500 | $54.01 | 439 |
| 2024 Q1 | 57,288,998 | $3,904,937,558 | +$217,314,654 | $68.16 | 469 |
| 2023 Q4 | 55,520,285 | $3,475,779,179 | +$42,550,297 | $62.60 | 465 |
| 2023 Q3 | 54,993,134 | $2,496,662,136 | -$1,898,845 | $45.39 | 400 |
| 2023 Q2 | 54,718,539 | $3,071,120,295 | -$80,853,798 | $56.14 | 409 |
| 2023 Q1 | 56,199,828 | $2,540,792,585 | +$38,754,979 | $45.23 | 375 |
| 2022 Q4 | 55,494,852 | $2,255,613,450 | -$74,822,214 | $40.65 | 386 |
| 2022 Q3 | 56,683,321 | $3,701,432,142 | -$78,744,860 | $65.35 | 410 |
| 2022 Q2 | 55,502,675 | $3,344,489,851 | +$271,662,077 | $60.77 | 404 |
| 2022 Q1 | 49,481,600 | $3,107,777,604 | +$483,746,495 | $62.77 | 415 |
| 2021 Q4 | 42,884,873 | $3,253,105,466 | +$73,035,179 | $75.78 | 425 |
| 2021 Q3 | 40,405,115 | $4,522,264,525 | -$41,114,506 | $111.93 | 458 |
| 2021 Q2 | 40,533,549 | $6,560,272,742 | -$153,120,996 | $161.89 | 484 |
| 2021 Q1 | 42,643,720 | $5,195,793,257 | -$576,803,869 | $121.85 | 431 |
| 2020 Q4 | 47,170,730 | $7,222,892,447 | +$35,286,644 | $153.11 | 397 |
| 2020 Q3 | 47,858,309 | $4,002,814,216 | +$723,322,979 | $83.64 | 300 |
| 2020 Q2 | 38,277,395 | $2,809,424,935 | +$279,188,892 | $73.49 | 263 |
| 2020 Q1 | 35,534,767 | $1,506,022,854 | +$153,360,658 | $42.41 | 244 |